Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Diabetes is a major risk factor for heart failure (HF). Patients with diabetes have a high incidence of both clinical HF and subclinical LV dysfunction. Although intensive glucose lowering does not appear to impact on HF outcomes, the choice of glucose-lowering agents plays an important role in the development of HF and related cardiovascular outcomes. Whilst metformin and insulin appear to have little impact on HF progression, the role of sulphonylurea agents in this patient population remains uncertain. Thiazolidinediones (TZDs) are associated with a significant risk of HF progression and are best avoided in patients at risk. The incretin-based therapies (GLP agonists and DPP-4 inhibitors) are generally not associated with any HF interaction. However, a small increase in HF admissions was observed with the DPP-4 inhibitor saxagliptin. The GLP-1 agonist liraglutide was recently shown to reduce cardiovascular and all-cause mortality, yet hospitalization for HF was not significantly reduced. The SGLT2 inhibitor empagliflozin was shown to reduce HF admissions and cardiovascular mortality in patients with prior cardiovascular disease including HF. These recent data showing improved outcomes with a glucose-lowering category provide a novel strategy to improve survival and reduce morbidity in diabetic patients at high cardiovascular disease risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Self-citationCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Self-citationMacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Self-citationTzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Self-citationHeart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp604 · Cited by 234
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Gerstein, H. C. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1699 · Cited by 217
Smooke, S., Horwich, T. B., & Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.005 · Cited by 196
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123
Research works printed but not linked: 41
- Schocken, 2008, Circulation, 117, 2544, 10.1161/CIRCULATIONAHA.107.188965 · DOI · Paper page
- Kannel, 1974, Role of diabetes in congestive heart failure: the Framingham study, Am J Cardiol, 34, 29, 10.1016/0002-9149(74)90089-7 · DOI · Paper page
- Dei Cas, 2015, Concomitant diabetes mellitus and heart failure, Curr Probl Cardiol, 40, 7, 10.1016/j.cpcardiol.2014.09.002 · DOI
- Lund, 2014, Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction, Eur J Heart Fail, 16, 992, 10.1002/ejhf.137 · DOI
- Bertoni, 2004, Heart failure prevalence, incidence, and mortality in the elderly with diabetes, Diabetes Care, 27, 699, 10.2337/diacare.27.3.699 · DOI · Paper page
- Cubbon, 2013, Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology, Diab Vasc Dis Res, 10, 330, 10.1177/1479164112471064 · DOI · Paper page
- Cubbon, 2014, Prospective development and validation of a model to predict heart failure hospitalisation, Heart, 100, 923, 10.1136/heartjnl-2013-305294 · DOI · Paper page
- Gotsman, 2014, Impaired fasting glucose: a predictor of reduced survival in patients with heart failure, Eur J Heart Fail, 16, 1190, 10.1002/ejhf.146 · DOI
- Poulsen, 2010, Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease, Circ Cardiovasc Imaging, 3, 24, 10.1161/CIRCIMAGING.109.855510 · DOI
- Fang, 2004, Relationship between longitudinal and radial contractility in subclinical diabetic heart disease, Clin Sci (Lond), 106, 53, 10.1042/CS20030153 · DOI · Paper page
- Nakai, 2009, Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration, Eur J Echocardiogr, 10, 926, 10.1093/ejechocard/jep097 · DOI
- McMurray, 2014, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored, Lancet Diabetes Endocrinol, 2, 843, 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
- Aguilar, 2009, Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes, J Am Coll Cardiol, 54, 422, 10.1016/j.jacc.2009.04.049 · DOI · Paper page
- Leung, 2016, Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus, Circ Cardiovasc Imaging, 9, 10.1161/CIRCIMAGING.115.003643 · DOI
- Pocock, 2006, Predictors of mortality and morbidity in patients with chronic heart failure, Eur Heart J, 27, 65, 10.1093/eurheartj/ehi555 · DOI · Paper page
- Skott, 1989, Effects of insulin on kidney function and sodium excretion in healthy subjects, Diabetologia, 32, 694, 10.1007/BF00274259 · DOI
- Rocchini, 1989, Insulin and renal sodium retention in obese adolescents, Hypertension, 14, 367, 10.1161/01.HYP.14.4.367 · DOI · Paper page
- 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, 1998, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- Eurich, 2013, Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients, Circ Heart Fail, 6, 395, 10.1161/CIRCHEARTFAILURE.112.000162 · DOI · Paper page
- McAlister, 2008, The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy, Eur J Heart Fail, 10, 703, 10.1016/j.ejheart.2008.05.013 · DOI · Paper page
- Nesto, 2003, American Heart Association, American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003, Circulation, 108, 2941, 10.1161/01.CIR.0000103683.99399.7E · DOI · Paper page
- Gilbert, 2015, Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy, Lancet, 385, 2107, 10.1016/S0140-6736(14)61402-1 · DOI · Paper page
- Karalliedde, 2007, Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies, Drug Saf, 30, 741, 10.2165/00002018-200730090-00002 · DOI
- Emoto, 2006, Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione, Diabetologia, 49, 2217, 10.1007/s00125-006-0313-5 · doi:10.1007/s00125-006-0313-5
- St John Sutton, 2002, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes, Diabetes Care, 25, 2058, 10.2337/diacare.25.11.2058 · DOI · Paper page
- Dargie, 2007, A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure, J Am Coll Cardiol, 49, 1696, 10.1016/j.jacc.2006.10.077 · DOI · Paper page
- Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
- Nikolaidis, 2004, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy, Circulation, 110, 955, 10.1161/01.CIR.0000139339.85840.DD · DOI · Paper page
- Margulies, 2014, GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study, Circ Heart Fail, 7, 673, 10.1161/CIRCHEARTFAILURE.114.000346 · DOI · Paper page
- Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035 · DOI · Paper page
- Hocher, 2012, Renal and cardiac effects of DPP4 inhibitors—from preclinical development to clinical research, Kidney Blood Press Res, 36, 65, 10.1159/000339028 · DOI
- Zannad, 2015, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, 385, 2067, 10.1016/S0140-6736(14)62225-X · DOI · Paper page
- Filion, 2016, A multicenter observational study of incretin-based drugs and heart failure, N Engl J Med, 374, 1145, 10.1056/NEJMoa1506115 · DOI · Paper page
- Yu, 2015, Incretin-based drugs and the risk of congestive heart failure, Diabetes Care, 38, 277, 10.2337/dc14-1459 · DOI · Paper page
- Majewski, 2015, Blood pressure reduction: an added benefit of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes, Diabetes Care, 38, 429, 10.2337/dc14-1596 · DOI · Paper page
- Desai, 2013, Hemoglobin concentration in acute decompensated heart failure: a marker of volume status?, J Am Coll Cardiol, 61, 1982, 10.1016/j.jacc.2013.02.021 · DOI
- Duarte, 2015, Prognostic value of estimated plasma volume in heart failure, JACC Heart Fail, 3, 886, 10.1016/j.jchf.2015.06.014 · DOI · Paper page
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, 1991, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 · DOI · Paper page
- 1999, Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 · DOI · Paper page
- Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 · DOI · Paper page
Cited by
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
Self-citationTomasoni, D., Adamo, M., Lombardi, C. M., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 258
McMurray, J. J. V., Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D., & Krum, H. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.004 · Cited by 165
Metadata
- Authors
- Fitchett, D. H., Udell, J. A., & Inzucchi, S. E.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09-21
- Volume
- 19
- Issue
- 1
- Pages
- 43-53
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2464585615
- Cited by
- 102
- References
- 34
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.